Learn Mode

PODD - Insulet Corp

46

$162.50

-$20.37 (-11.139%)

4/29/26, 6:21 PM

Score

4.03/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

PODD

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$12.32B

Industry

Health Care

EPS (TTM)

$3.50

P/E (TTM)

49.88

Div & Yield

FCF Payout Ratio

P/S (TTM)

4.55

P/B

8.13

Diluted Shares

70.67M

Ex-Dividend

Next Earnings

05-06

Forward P/E

23.81

Payout Ratio

P/FCF (TTM)

35.23

FCF Yield

2.84%

Earnings Yield

2.00%

52 Week Range

Score Card

Explore Scores Tab

4.03

Good

Insulet Corp has grown revenue at 30.73% over the past year, which is strong growth. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

3.00

Average

Management

3.00

Average

Growth

5.00

Very Good

Profitability

3.00

Average

Fin. Health

4.00

Good

Dividends

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-06 16:07:20

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-06 16:05:56

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:14:00

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:10:28

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:08:04

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 09:51:32

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-12 16:06:56

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-04 16:06:27

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:52:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:49:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:48:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:47:20

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-12

High:

$456.75

181.1%

Avg:

$357.29

119.9%

Low:

$232.30

43.0%

(% change is relative to the current stock price: $162.50)

Analyst Recommendations

Go to Analyst Tab

4.26

Very Good

38%

Strong Buy (13)

53%

Buy (18)

Hold (2)

Sell (1)

Strong Sell (0)

About

Website
https://www.omnipod.com
Address
100 Nagog Park, Acton MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1145197

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

IPO Date

2007-05-15

Industry

Health Care

Total Employees

5,400

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services

PODD - Insulet Corp

46

$162.50

-$20.37 (-11.139%)

4.03/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form DEFA14A

Filed on 2026-04-06 16:07:20

Form DEF 14A

Filed on 2026-04-06 16:05:56

Form 4

Filed on 2026-04-02 16:14:00

Form 3

Filed on 2026-04-02 16:10:28

Form 4

Filed on 2026-04-02 16:08:04

Form SCHEDULE 13G/A

Filed on 2026-03-27 09:51:32

Form 8-K

Filed on 2026-03-12 16:06:56

Form 8-K

Filed on 2026-03-04 16:06:27

Form 4

Filed on 2026-03-03 18:52:08

Form 4

Filed on 2026-03-03 18:49:55

Form 4

Filed on 2026-03-03 18:48:41

Form 4

Filed on 2026-03-03 18:47:20

Financials

Price Targets

181.1%

119.9%

43.0%

Analyst Recommendations

About

Similar Stocks